COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hepatic Inflammation and Physical Performance in Patients With NASH (HELP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02526732
Recruitment Status : Completed
First Posted : August 18, 2015
Last Update Posted : September 5, 2018
Information provided by (Responsible Party):
Priv.-Doz. Dr. J. Schattenberg, Johannes Gutenberg University Mainz

Brief Summary:
The aim of the study is to examine the influence of hepatic inflammation or damage on physical performance (maximal oxygen uptake, VO2max) depending on the histologic state of the liver. The study population are patients with fatty liver disease and non-alcoholic steatohepatitis (NASH). All study participants obtain an individual training plan with individual and group training sessions for a period of 8 weeks. At the beginning and end of the training phase a sport physiological examination is carried out. In the study group the effect of regular examinations is surveyed by surrogate parameters of liver inflammation.

Condition or disease Intervention/treatment Phase
Non-alcoholic Fatty Liver Disease Other: individual training program Not Applicable

Detailed Description:
The study is planned over a period of 24 months. Study participants should be twice examined sport physiologically in a period of 12 weeks. In the study group the influence of regular exercise on surrogate parameters of liver inflammation is investigated over a study period of 8 weeks. Before the exercise all study participants are subjected to a first physiological examination (about 3 hours). This includes a physical examination with detection of body weight, waist circumference and body fat analysis, venous blood, oral glucose tolerance test, ultrasonography of the liver and determination of endothelial function (flow-mediated vasodilatation, FMD) by Doppler analysis. Within 4 weeks after the first examination a sport physical examination is carried out at the Institute of Sports Science at the University of Mainz. This examination contains identification of physical fitness and individual lactate performance diagnostics. In addition, indirect calorimetry is carried out under exercise conditions using spiroergometry to determine the maximal oxygen uptake (VO2max) with special emphasis on the fat metabolism rate at low physical activity. Subsequently to the examination an 8-week training period based on individual training / performance plans is followed. The training plans include independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician. Within the planed four groups training sessions blood samples will be taken to determinate free circulating DNA and assess lactate values under exercise conditions. After the training phase, a second sport physical examination including physical performance and a final physiological examination including surrogate parameters of liver inflammation are carried out. For statistical analysis, the physical performance of the study participants is examined. Hence patients with histologically proven NASH (NAS score) and confirmed inflammation (increased M30 antigen) are compared to age and gender matched patients with histologically proven fatty liver without inflammation reaction as well as to retrospective data of healthy subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis
Study Start Date : September 2015
Actual Primary Completion Date : December 20, 2017
Actual Study Completion Date : December 20, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Health Checkup

Arm Intervention/treatment
Experimental: individual training program
Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.
Other: individual training program
Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.

Primary Outcome Measures :
  1. Change in physical performance [ Time Frame: 0-8 weeks ]
    Change of Vo2max from week 0 to week 8

Secondary Outcome Measures :
  1. Change in liver inflammation [ Time Frame: 8 weeks ]
    Change of NAS score at week 0 and week 8

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • histologically proven NASH or fatty liver disease

Exclusion Criteria:

  • bariatric surgery within the last 5 years
  • BMI< 18,5 kg/m2 or > 45 kg/m2
  • heart attack or stroke within the last 6 months
  • higher-grade coronary artery disease (CAD III-IV)
  • chronic obstructive pulmonary disease (asthma , COPD)
  • renal insufficiency
  • uncontrolled hypertension or metabolic abnormalities
  • alcohol consumption > 30 g / day (male) and > 20 g / day (female)
  • pregnancy
  • concomitant medication able to cause a secondary NASH (eg tamoxifen , corticosteroids )
  • concomitant medication able to affect inflammation (eg TNF antagonists)
  • concomitant anticoagulant medication (eg phenprocoumon, NOAC)
  • other immunological or inflammatory diseases (eg, systemic lupus erythematosus)
  • musculoskeletal disorders, preventing sport physiological investigations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02526732

Layout table for location information
University Medical Center of the Johannes Gutenber Univeristy
Mainz, Germany, 55131
Sponsors and Collaborators
Priv.-Doz. Dr. J. Schattenberg
Layout table for investigator information
Study Director: Peter R Galle, MD I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Priv.-Doz. Dr. J. Schattenberg, Prov.-Doz. Dr. med., Johannes Gutenberg University Mainz Identifier: NCT02526732    
Other Study ID Numbers: 2015_04_001_HELP
First Posted: August 18, 2015    Key Record Dates
Last Update Posted: September 5, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Publication in scientific journals and conferences
Keywords provided by Priv.-Doz. Dr. J. Schattenberg, Johannes Gutenberg University Mainz:
fatty Liver
VO2 max
M30 antigen
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Pathologic Processes
Digestive System Diseases